E02_07 Diabetes Flashcards
2017, 2018_Diabetes
Based on efficacy criteria, which among the following drugs is considered the most effective in lowering HbA1c?
A. Megletinides/glinides
B. DPP4 inhibitors
C. Biguanides
D. Thiazolidinediones
C. Biguanides
2017, 2018_Diabetes
Which of the following drugs causes the most episodes of hypoglycemia?
A. Biguanides
B. Thiazolidinediones
C. Meglitinides
D. Sulfunylureas
D. Sulfunylureas
2017, 2018_Diabetes
You have a newly diagnosed 57 year old diabetic patient with an estimated GFR of 20. Which of the following drugs is contraindicated?
A. Insulin
B. DPP4 inhibitors
C. Metformin
D. Meglitinides/glinides
C. Metformin
2017, 2018_Diabetes
The usual starting dose of Metformin is:
A. 500 mg 3x a day before eating
B. 500 mg 3x a day after eating
C. 500 mg 2x a day before eating
D. 500 mg x2 a day after eating
D. 500 mg x2 a day after eating
2017, 2018_Diabetes
You have a 48 year old patient who is consulting you for the first time for diabetes. His FBS is 2– mg/dL and his HbA1c is 92%. According to the Philippine guideline your P-drug for this patient will be which of the following?
A. Sulfunylureas
B. Metformin
C. Combination therapy of 2 anti-diabetic drugs
D. Basal insulin alone
C. Combination therapy of 2 anti-diabetic drugs
2017, 2018_Diabetes
Which of the following drugs has a glucose dependent mechanism of action for suppression of glucagon and stimulates insulin production?
A. Megletinides/glinides
B. Biguanides
C. Incretin or incretin-based therapy
D. Thiazolidinediones
C. Incretin or incretin-based therapy
2017_Diabetes
You have a patient with diabetes with a BMI of 32 kg/m2. Which of the following drugs is the best treatment due to its side effect of weight loss?
A. DPP4 inhibitors
B. Sulfonylureas
C. Thiazolidinediones
D. Incretins
D. Incretins
2017, 2018_Diabetes
Your 62 year old diabetic patient is currently consulting for bipedal edema ans easy fatiguability. You suspect CHF and upon audit of his medications you decided to remove one of them. Which of the following is the drug you will most likely remove from his prescription?
A. Pioglitazone
B. Repaglinide
C. Sitagliptin
D. Glicazine
A. Pioglitazone
AE of Thiazolidinediones (e.g. Pioglitazone) - CHF, Edema, Bone Fractures, Bladder CA, weight gain
2017_Diabetes
Which of the following are long acting second generation sulfunylureas?
A. Glibenclamide
B. Chlorpropamide
C. Nateglinide
D. Glimepiride
A. Glibenclamide
*Answer key says D. Glimepiride
Glimepiride is 3rd gen in some references, medium- to long-acting
2017, 2018_Diabetes
Example of a drug that work by inhibiting the SGLT-2 in the proximal convoluted tubule of the kidneys:
A. Repaglinide
B. Dapaglifozin
C. Sitagliptin
D. Rosiglitazone
B. Dapaglifozin
Glinides = Meglitinides Gliflozins = SGLT2 Gliptins = DPP4 Glitazones = TZDs
2017_Diabetes
Glycemic target for a 72 year old patient with a creatinine clearance of 24 ml/min, who has suffered a stroke and has right sided hemiparesis:
A. FBS of 180-200 mg/dL
B. HbA1c of
B. HbA1c of
2017_Diabetes
Drug of choice for a diabetic patient with hepatic failure due to chronic active hepatitis B:
A. DPP4 inhibitors
B. Alpha glucosidase
C. Insulin
D. SGLT-2 inhibitors
C. Insulin
2018_Diabetes
Which of the following guidelines considers patient values and preferences in deciding on the P drug?
A. American Diabetes Association - EASD
B. American Association of Clinical Endocrinology
C. International Diabetes Federation
D. Canadian Diabetes Association
A. American Diabetes Association - EASD
2018_Diabetes
Drug of choice as monotherapy for most patients with type 2 DM?
A. Metformin
B. Sulfonylureas
C. TZDs
D. DPP4 inhibitors
A. Metformin
2018_Diabetes
Which of the following agents is ideal for use in obese patients for its weight losing capacity?
A. DPP4 inhibitors
B. Sulfonylureas
C. Thiazolidinediones
D. SGLT2 inhibitors
D. SGLT2 inhibitors
> Weight loss:
- Biguanides
- SGLT2 Inhibitors
- GLP1 Receptor Agonists
> Weight gain:
- SU
- Meglitinides
- TZDs
*DPP4 (-gliptins) - weight neutral